HER2+ Breast Cancer

A supplemental new drug application has been submitted to Japan’s Ministry of Health, Labour, and Welfare or the use of fam-trastuzumab deruxtecan-nxki as a treatment in select patients with HER2-positive unresectable or recurrent breast cancer.

Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.

A panel of breast cancer experts shared their insights on 4 recently approved targeted therapies for patients with relapsed HER2-positive metastatic breast cancer.

Gretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.

The first patient with high-risk, early-stage HER2-positive breast cancer has received a dose of neoadjuvant fam-trastuzumab deruxtecan-nxki as part of the global, phase 3 DESTINY-Breast11 trial.

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Prior research has shown that the combination of trastuzumab deruxtecan plus pertuzumab may be superior to T-trastuzumab deruxtecan alone in patients with HER2-positive metastatic breast cancer and the combination is now under examination in the phase 3 DESTINY-Breast09 trial.

Deborah L. Toppmeyer, MD, discusses clinical trials involving treatments for HER2-positive and triple-negative breast cancer, as well as the importance of making these trials accessible to all patient populations in an attempt to address disparities.

Neil Vasan, MD, PhD, discusses future research directions for approved agents used in the treatment of patients with HER2-positive breast cancer.

Neil Vasan, MD, PhD, discussed the emergence of de-escalated treatment strategies for patients with HER2-positive breast cancer, pivotal trials that have shifted standards in clinical practice, and next steps for research.

Carla Falkson, MBChB, MMed, MD, discusses opportunities for de-escalating therapy in patients with HER2-positive breast cancer. 

Gretchen G. Kimmick, MD, MS, discusses the quickly evolving treatment paradigm for patients with HER2-positive breast cancer. 

Mothaffar Fahed Rimawi, MD, discusses future research directions in metastatic HER2-positive breast cancer. 

Sarah Sammons, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

The phase 2 ACE-Breast03 trial has been launched to evaluate the efficacy and safety of ARX788, an investigational antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer who have progressed on prior HER2-directed therapies.

Francisco Javier Esteva, MD, PhD, discussed the current approach to treating patients with early-stage HER2-positive breast cancer, unmet needs in the space, and future directions with neratinib and T-DM1.

Vic-trastuzumab duocarmazine markedly improved progression-free survival vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received 2 prior treatment regimens or ado-trastuzumab emtansine in the metastatic setting, according to data from the phase 3 TULIP trial.

Nadia Harbeck, MD, PhD, discusses the predictive impact of biomarkers on pathologic complete response and survival following de-escalated neoadjuvant T-DM1 with or without endocrine therapy in patients with hormone receptor–positive, HER2-positive breast cancer.

Nadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.

Mothaffar Fahed Rimawi, MD, discusses mitigating interstitial lung disease/pneumonitis in HER2-positive breast cancer.

The FDA has granted a breakthrough therapy designation to trastuzumab deruxtecan-nxki for use in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 1 or more anti–HER2-based regimens.